Related Experiment Videos
Tolerance study of ceftriaxone compared with amoxicillin in patients with pneumonia
Abstract:
The safety of ceftriaxone was compared with that of amoxicillin in a randomized study of 91 patients with community-acquired pneumonia. The origin of infection was similar in the two groups. It was proven or probable Streptococcus pneumoniae in 50 percent of the patients and remained uncertain in 40 percent. Ninety percent of the patients who received ceftriaxone were clinically cured compared with 69 percent of those given amoxicillin (p less than 0.05). However, this difference was not apparent among the patients with proven or probable pneumococcal pneumonia. No severe clinical side effects were observed. Cutaneous reactions were more prevalent in the amoxicillin group, whereas mild diarrhea and mucosal candidiasis were more frequent in the ceftriaxone group. Reversible neutropenia was observed in two patients treated with ceftriaxone and none of those treated with amoxicillin.
Insights
Ceftriaxone demonstrated higher clinical cure rates for community-acquired pneumonia than amoxicillin, although this was not seen in Streptococcus pneumoniae cases. Both antibiotics were generally safe, with different side effect profiles.
Area of Science:
- Infectious Diseases
- Pharmacology
- Clinical Medicine
Background:
- Community-acquired pneumonia (CAP) is a significant global health concern.
- Antibiotic resistance necessitates ongoing evaluation of treatment efficacy.
- Streptococcus pneumoniae is a common pathogen in CAP.
Purpose of the Study:
- To compare the clinical efficacy and safety of ceftriaxone versus amoxicillin in treating CAP.
- To assess treatment outcomes based on the identified causative pathogen.
Main Methods:
- A randomized study involving 91 patients diagnosed with community-acquired pneumonia.
- Patients were treated with either ceftriaxone or amoxicillin.
- Clinical cure rates and adverse events were systematically recorded.
Main Results:
- Ceftriaxone achieved a 90% clinical cure rate, significantly higher than amoxicillin's 69% (p<0.05).
- This difference was not observed in patients with confirmed or probable Streptococcus pneumoniae infections.
- Adverse events included more cutaneous reactions with amoxicillin and mild diarrhea/candidiasis with ceftriaxone. Two cases of reversible neutropenia occurred with ceftriaxone.
Conclusions:
- Ceftriaxone may offer superior clinical outcomes for CAP compared to amoxicillin overall.
- Treatment effectiveness may be pathogen-dependent, particularly for Streptococcus pneumoniae.
- Both agents exhibited acceptable safety profiles with distinct adverse event patterns.